The QICAOGANGMU Experience: Immediate Relief vs Long-Term Skin Healing (2026)

By Ava Huang, Herbal Science Researcher at QICAOGANGMU | Updated: May 2026 | Reading time: 9 minutes

One of the most common questions from new QICAOGANGMU users is: "How fast will this work?" The answer has two parts - because QICAOGANGMU is doing two different things at once. Within minutes of application, Menthol and Borneolum provide immediate cooling relief from itch and discomfort. Over the following days and weeks, Sophora flavescens, Cnidii Fructus, and Stemonae Radix address the underlying inflammatory mechanisms that drive chronic skin conditions. This article explains exactly how each phase works, why it takes the time it does, and what to expect at each stage.

Quick reference: QICAOGANGMU timeline

Phase 1: Immediate relief - what happens in the first minutes

Menthol: TRPM8 cooling within minutes

Menthol (0.5%) activates TRPM8 cold thermoreceptors in the skin within minutes of application, creating a cooling sensation that competitively overrides the itch signal in cutaneous nerve fibres. PMID 17498839. This is not a numbing or anaesthetic effect - it is a receptor-level override that breaks the itch-scratch cycle at the nerve ending. A clinical study confirmed TRPM8 agonist creams produce significant antipruritic effects in atopic dermatitis patients. PMID 30067875

Eczema itch is characteristically worst at night, disrupting sleep and contributing to the stress that further worsens inflammation. Menthol's fast-acting TRPM8 mechanism is specifically effective for this evening itch cycle.

Borneolum: the penetration enabler and direct antipruritic

Borneolum Syntheticum (2%) does two things simultaneously from the moment of application:

• Penetration enhancement: Borneol temporarily disrupts lipid packing in the stratum corneum, creating transient micro-channels that increase the transdermal absorption of all co-applied actives - including Menthol, Ku Shen, and She Chuang Zi. PMC5452010. This is why QICAOGANGMU works faster than single-ingredient products: Borneolum delivers everything else deeper and faster.
• Direct antipruritic: Borneol relieves non-histaminergic pruritus via TRPA1 inhibition and TRPM8 activation, complementing Menthol's cooling effect with a separate receptor pathway. PMID 37290679, PMID 38103845

Together Menthol and Borneolum also regulate TRPM8, TRPV1, and TRPA1 receptor expression synergistically, providing combined anti-inflammatory activity beyond either alone. PMID 39017810

Phase 2: Long-term healing - what happens over days and weeks

Sophora flavescens (Ku Shen) - 1.5%: the anti-inflammatory core

NF-kB inhibition is the central mechanism. Matrine, oxymatrine, sophoraflavanone G, and kushenol F from Ku Shen suppress pro-inflammatory cytokines IL-6, IL-8, CXCL1, TNF-alpha, and IL-1beta - the molecular drivers of eczema and psoriasis inflammation. PMID 38358770

This is why consistency matters: NF-kB modulation requires sustained herbal compound levels in the skin. Unlike steroids which produce immediate receptor-level suppression, Ku Shen's effect builds with twice-daily application over 1-2 weeks before producing visible redness reduction. The trade-off is that there is no steroid rebound when it is stopped - the effect simply fades rather than causing a rebound flare.

Ku Shen also addresses itch through a separate pathway from Menthol: kushenol F suppresses TSLP (thymic stromal lymphopoietin) at the cellular level - reducing the cytokine that activates itch neurons. PMID 36355519. Antipruritic action via histamine-independent pathways. PMID 12736520

Cnidii Fructus (She Chuang Zi) - 3%: chronic itch and barrier repair

Osthole, the primary active coumarin from She Chuang Zi, inhibits TRPV3 channels - a neurogenic itch receptor that is upregulated in atopic dermatitis skin. PMID 30108138. This desensitisation process takes days rather than minutes, explaining why users notice progressively less itch over the first 1-2 weeks rather than immediate cessation.

Osthole also supports skin barrier repair via Akt/ZO-3 pathway modulation in atopic dermatitis models - a barrier repair mechanism that addresses the compromised ceramide structure underlying eczema. PMID 36921706. The comprehensive pharmacology review confirms antipruritic, anti-allergic, antifungal, and barrier repair activity. PMC7229549, PMC7037677

Stemonae Radix (Bai Bu) - 0.5%: sustained antimicrobial defence

Staphylococcus aureus colonises over 90% of eczema-affected skin and directly amplifies the inflammatory cytokine cascade - worsening both itch and visible inflammation. Stemonae Radix alkaloids provide sustained antibacterial activity against Staph aureus and anti-inflammatory action via COX-2 and NO suppression. PMID 35295975, PMID 38331134

This antimicrobial coverage explains why users with weeping or infected-appearing eczema often see faster improvement with QICAOGANGMU than with conventional anti-inflammatory creams alone - the Staph contribution to the inflammation is being addressed simultaneously.

Why consistency determines results

Phase 1 relief (cooling, itch override) occurs with every application. Phase 2 healing (NF-kB modulation, TRPV3 desensitisation, barrier repair) requires sustained herbal compound levels in the skin tissue - which only builds with consistent twice-daily application.

This is the fundamental difference from steroids: a steroid cream produces full effect from the first application because it works by switching off the immune response broadly. Ku Shen's NF-kB modulation requires accumulation over time - but it does this without creating the dependency that makes stopping steroids so difficult.

A systematic review confirmed the efficacy of topical Chinese herbal medicine for atopic eczema with a good safety profile for long-term use. PMID 24821063. The formulae and biologically active ingredients of Chinese herbal medicines for atopic dermatitis have been comprehensively reviewed. PMID 26243582

Practical guidance for each stage

• Week 1: Apply twice daily (morning and before bed). Focus on the immediate cooling relief - this is what makes the first week manageable. Do not judge results yet; the anti-inflammatory phase has barely begun.
• Weeks 2-4: Itch frequency should be reducing. Redness beginning to calm. Continue twice daily. This is the critical period - stopping early here interrupts the NF-kB modulation before it is established.
• Months 1-3: Visible improvement in skin texture and reduced flare frequency. Reduce to once daily for maintenance. The herbs are now maintaining skin balance rather than correcting acute inflammation.
• TSW patients: Expect a rebound flare in weeks 1-3 from the steroids, not from QICAOGANGMU. Continue applying through it - Menthol and Borneolum provide itch relief during this phase without adding any steroid compound.

Frequently asked questions

How quickly does QICAOGANGMU start working?

Itch cooling begins within minutes of first application (Menthol TRPM8 activation). Visible reduction in redness and inflammation typically begins within 5-14 days of consistent twice-daily use as Ku Shen's NF-kB modulation accumulates in the skin. Users who apply inconsistently (some days but not others) consistently report slower results - this matches the pharmacology exactly.

Why does it take longer than a steroid cream?

Steroid creams work by broadly suppressing the immune response from the first application - fast, powerful, and immediately visible. Ku Shen's NF-kB inhibition is a modulating mechanism that requires compound accumulation in skin tissue. It is slower because it is targeted rather than broad. The trade-off is no skin thinning, no rebound, and no dependency - which is why it is safe for daily long-term use where steroids are not.

When should I see long-term improvement?

Most users notice significantly reduced flare frequency and severity after 4-8 weeks of consistent twice-daily use. This aligns with published systematic review evidence for topical Chinese herbal medicine. PMID 24821063. Full skin barrier repair takes approximately one full skin cell turnover cycle - 28-42 days in adults - so 6-8 weeks is a meaningful first assessment point.

Should I continue using QICAOGANGMU when my skin is clear?

Yes - once daily maintenance application after symptoms clear is recommended, not just for eczema management but because it is safe to do so. Unlike topical steroids that require treatment breaks to avoid skin atrophy, QICAOGANGMU is steroid-free and designed for continuous long-term use without dose restrictions. Stopping completely when skin clears often leads to a return of symptoms within weeks as the herbal protection is withdrawn.

Can I use QICAOGANGMU alongside steroid creams?

Yes - apply steroid cream first to the inflamed area for acute flare control, allow it to absorb, then apply QICAOGANGMU to the surrounding areas and to maintain protection during remission periods. Many people use this approach to reduce their overall steroid usage while maintaining symptom control. See our detailed guide at QICAOGANGMU vs steroid creams.

Related articles

• QICAOGANGMU Ingredients: Full Breakdown of Every Herb, Concentration and Safety Evidence
• QICAOGANGMU vs Steroid Creams: Key Differences, Side Effects and Safety
• How to Use QICAOGANGMU Cream for Optimal Results

Clinical references

1. He X et al. Sophora flavescens: Traditional usage, phytochemistry and pharmacology. Journal of Ethnopharmacology. 2015;172:10-29. PMID 26087234
2. Pan YJ et al. Anti-inflammatory activity of flavonoids and alkaloids from Sophora flavescens alleviates psoriasiform lesions. Phytotherapy Research. 2024;38(4):1951-1970. PMID 38358770
3. Antipruritic effects of Sophora flavescens. PubMed. 2003. PMID 12736520
4. Jo S et al. Kushenol F suppresses TSLP in atopic dermatitis models. Pharmaceuticals. 2022;15(11):1347. PMID 36355519
5. Liu Y et al. Cnidium monnieri: A Review of Traditional Uses, Phytochemical and Pharmacology. Molecules. 2015;20(8):13778-98. PMID 26243582
6. Sun Y et al. Phytochemistry, ethnopharmacology, pharmacokinetics and toxicology of Cnidium monnieri. American Journal of Chinese Medicine. 2020;48(2):285-314. PMC7037677
7. Chen X et al. Antipruritic effect of ethyl acetate extract from Fructus cnidii in DNFB-induced atopic dermatitis mice. Frontiers in Pharmacology. 2020;11:621. PMC7229549
8. Sun X-Y et al. Antipruritic effect of natural coumarin osthole through selective inhibition of TRPV3 channels. International Journal of Molecular Sciences. 2018;19(10):3007. PMID 30108138
9. Hu X et al. Osthole relieves skin damage and inhibits chronic itch via Akt/ZO-3 modulation in atopic dermatitis. European Journal of Pharmacology. 2023;947:175649. PMID 36921706
10. Tian W et al. Topical borneol relieves nonhistaminergic pruritus via TRPA1 inhibition and TRPM8 activation. Journal of Investigative Dermatology. 2023;143(10):2389-2398. PMID 37290679
11. Li ZY et al. Borneol reduces acute and chronic itch by modulating TRPA1 and TRPM8. Frontiers in Pharmacology. 2023;14:1288289. PMID 38103845
12. Gu Y et al. Borneol and Menthol regulate TRPM8, TRPV1, and TRPA1 expression in HaCaT cells. Evidence Based Complementary and Alternative Medicine. 2024. PMID 39017810
13. Dai H et al. Clinical and mechanistic study of topical borneol-induced analgesia. Experimental and Therapeutic Medicine. 2017;13(6):3267-3272. PMC5452010
14. Patel T, Ishiuji Y, Yosipovitch G. Menthol: a refreshing look at this ancient compound. Journal of the American Academy of Dermatology. 2007;57(5):873-878. PMID 17498839
15. Misery L et al. Anti-itching effects of a TRPM8 agonist cream in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2019;33(2):e67-e69. PMID 30067875
16. Xu Y et al. Alkaloids from Stemona tuberosa and their anti-inflammatory activity. Frontiers in Chemistry. 2022;10:847595. PMID 35295975
17. Zhang N et al. Isolation, characterization and anti-inflammatory effect of alkaloids from the roots of Stemona tuberosa. Phytochemistry. 2024;220:114013. PMID 38331134
18. Gu S et al. Topical Chinese herbal medicine for atopic eczema: systematic review with meta-analysis. Dermatology. 2014. PMID 24821063